MA49576A - Compositions et méthodes pour le traitement d'infections fongiques - Google Patents

Compositions et méthodes pour le traitement d'infections fongiques

Info

Publication number
MA49576A
MA49576A MA049576A MA49576A MA49576A MA 49576 A MA49576 A MA 49576A MA 049576 A MA049576 A MA 049576A MA 49576 A MA49576 A MA 49576A MA 49576 A MA49576 A MA 49576A
Authority
MA
Morocco
Prior art keywords
compositions
treatment
methods
fungal infections
fungal
Prior art date
Application number
MA049576A
Other languages
English (en)
Inventor
Kenneth Bartizal
Paul Daruwala
David Hughes
Martin Patrick Hughes
Navdeep B Malkar
Balasingam Radhakrishnan
Anuradha Vaidya
Original Assignee
Cidara Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cidara Therapeutics Inc filed Critical Cidara Therapeutics Inc
Publication of MA49576A publication Critical patent/MA49576A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA049576A 2017-07-12 2018-07-11 Compositions et méthodes pour le traitement d'infections fongiques MA49576A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762531788P 2017-07-12 2017-07-12

Publications (1)

Publication Number Publication Date
MA49576A true MA49576A (fr) 2021-04-07

Family

ID=65002328

Family Applications (1)

Application Number Title Priority Date Filing Date
MA049576A MA49576A (fr) 2017-07-12 2018-07-11 Compositions et méthodes pour le traitement d'infections fongiques

Country Status (7)

Country Link
US (2) US11197909B2 (fr)
EP (1) EP3651801A4 (fr)
JP (2) JP2020529973A (fr)
CN (1) CN111050798A (fr)
CA (1) CA3069423A1 (fr)
MA (1) MA49576A (fr)
WO (1) WO2019014333A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6117907B2 (ja) 2012-03-19 2017-04-19 シダラ セラピューティクス インコーポレーテッド エキノキャンディン系化合物のための投与レジメン
EP3399995A4 (fr) 2016-01-08 2019-08-21 Cidara Therapeutics, Inc. Procédés de prévention et de traitement d'infections à pneumocystis
CA3017485A1 (fr) 2016-03-16 2017-09-21 Cidara Therapeutics, Inc. Schemas posologiques pour le traitement d'infections fongiques
JP2020529973A (ja) 2017-07-12 2020-10-15 シダラ セラピューティクス インコーポレーテッド 真菌感染症の処置のための組成物及び方法
AU2019287621A1 (en) 2018-06-15 2021-01-28 Cidara Therapeutics, Inc. Synthesis of echinocandin antifungal agent
CN114606342B (zh) * 2022-04-24 2023-10-17 连云港市妇幼保健院(连云港市第三人民医院) 一种基于rpa—lfs快速检测***滑念珠菌的引物探针组合及其应用

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4427660A (en) 1982-03-03 1984-01-24 Research Corporation Formyl-methionyl chemotatic peptide antibiotic conjugates useful in treating infections
US5166135A (en) 1988-09-12 1992-11-24 Merck & Company, Inc. Method for the control of pneumocystis carinii
US6030944A (en) 1991-10-01 2000-02-29 Merck & Co., Inc. Cyclohexapeptidyl bisamine compounds
US5399552A (en) 1991-10-17 1995-03-21 Merck & Co, Inc Antibiotic peptides bearing aminoalkylthioether moieties
US5378804A (en) 1993-03-16 1995-01-03 Merck & Co., Inc. Aza cyclohexapeptide compounds
US6268338B1 (en) 1993-04-30 2001-07-31 Merck & Co., Inc. Cyclohexapeptidyl amine compounds
US5948753A (en) 1993-05-04 1999-09-07 Merck & Co., Inc. Cyclohexapeptidyl propanolamine compounds
JPH09500103A (ja) 1993-05-04 1997-01-07 メルク エンド カンパニー インコーポレーテッド シクロヘキサペプチジルアミノアルキルエーテル
WO1995008341A1 (fr) 1993-09-22 1995-03-30 Merck & Co., Inc. Composes antifongiques et anti-pneumocystose, compositions les contenant et procedes d'utilisation
US5541160A (en) 1994-04-04 1996-07-30 Merck & Co., Inc. Antifungal and anti-pneumocystis compounds, compositions containing such compounds, and methods of use
US5514651A (en) 1994-09-16 1996-05-07 Merck & Co., Inc. Aza cyclohexapeptide compounds
US5516756A (en) 1994-10-31 1996-05-14 Merck & Co., Inc. Aza cyclohexapeptide compounds
JP2966936B2 (ja) 1995-01-26 1999-10-25 メルク エンド カンパニー インコーポレーテッド 新規抗真菌シクロヘキサペプチド
US5652213A (en) 1995-05-26 1997-07-29 Eli Lilly And Company Cyclic peptide antifungal agents
AR006598A1 (es) 1996-04-19 1999-09-08 Merck Sharp & Dohme "composiciones anti-fungosas, su uso en la manufactura de medicamentos y un procedimiento para su preparación"
US6069126A (en) 1996-09-12 2000-05-30 Merck & Co., Inc. Antifungal combination therapy
ATE338059T1 (de) 1998-12-09 2006-09-15 Lilly Co Eli Reinigung von echinocandin cyclopeptiden
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
AU771727B2 (en) 1999-03-03 2004-04-01 Eli Lilly And Company Processes for making pharmaceutical oral ECB formulations and compositions
EP1582204B1 (fr) 1999-03-03 2013-09-25 Eli Lilly & Company Formulations pharmaceutiques d'échinocandine contenant des tensioactifs formant des micelles
US6309622B1 (en) 1999-03-26 2001-10-30 Protech Professional Products, Inc. Antimicrobial denture cleansing compositions
US6479532B1 (en) 1999-04-16 2002-11-12 Fujisawa Pharmaceutical Co., Ltd. Antifungal compositions
HU0104790D0 (en) 2001-11-08 2002-01-28 Human Rt Pharmaceutical combinations for topical application
US6991800B2 (en) 2002-06-13 2006-01-31 Vicuron Pharmaceuticals Inc. Antifungal parenteral products
US20060276339A1 (en) 2002-10-16 2006-12-07 Windsor J B Methods and compositions for increasing the efficacy of biologically-active ingredients
US6913759B2 (en) 2003-03-11 2005-07-05 Curatek Pharmaceuticals Holding, Inc. Gel composition and method for treatment of vaginal infections
ES2298821T3 (es) 2003-07-22 2008-05-16 Theravance, Inc. Utilizacion de un agente antifungico de equinocandina en combinacion con un agente antibacteriano glicopeptidico.
US20060140990A1 (en) 2003-09-19 2006-06-29 Drugtech Corporation Composition for topical treatment of mixed vaginal infections
US8753819B2 (en) 2005-07-26 2014-06-17 Rutgers, The State University Of New Jersey Assays for resistance to echinocandin-class drugs
US20070231258A1 (en) 2006-03-31 2007-10-04 Karyon Ctt Ltd. Peptide conjugates
GB0702020D0 (en) 2007-02-02 2007-03-14 Novabiotics Ltd Peptides and their use
US20090238867A1 (en) 2007-12-13 2009-09-24 Scott Jenkins Nanoparticulate Anidulafungin Compositions and Methods for Making the Same
US20100009009A1 (en) 2008-07-10 2010-01-14 Micropure, Inc. Method and composition for prevention and treatment of oral fungal infections
GB0817121D0 (en) 2008-09-18 2008-10-29 Univ St Andrews Anti-fungal therapy
AU2010217190B2 (en) 2009-02-25 2012-10-25 Mayne Pharma Llc Topical foam composition
US9006391B2 (en) 2009-05-07 2015-04-14 Dsm Sinochem Pharmaceuticals Netherlands B.V. Method for the preparation of cyclopeptides
NO2470168T3 (fr) 2009-08-26 2018-06-30
WO2011025875A1 (fr) 2009-08-27 2011-03-03 Seachaid Pharmaceuticals, Inc. Dérivés d’échinocandine
WO2011089214A1 (fr) 2010-01-22 2011-07-28 Ascendis Pharma As Lieurs de précurseurs à base de carbamates liés à des supports
EP2552529A4 (fr) * 2010-03-30 2014-01-01 Sparkmed Res Llc Sondes médicales, tubes et dispositifs libérant des médicaments
SI2680873T1 (sl) 2011-03-03 2017-12-29 Cidara Therapeutics, Inc. Protiglivna sredstva in njihova uporaba
WO2013017691A1 (fr) 2011-08-04 2013-02-07 Medizinische Universität Innsbruck Inhibiteurs de cahgtlp destinés à être utilisés dans le traitement de la candidiase
US8829053B2 (en) 2011-12-07 2014-09-09 Rochal Industries Llp Biocidal compositions and methods of using the same
JP6117907B2 (ja) 2012-03-19 2017-04-19 シダラ セラピューティクス インコーポレーテッド エキノキャンディン系化合物のための投与レジメン
CN102766198A (zh) 2012-05-04 2012-11-07 中国人民解放军第二军医大学 一种糖肽类抗真菌化合物及其制备方法与应用
WO2014113693A1 (fr) 2013-01-18 2014-07-24 University Of Utah Research Foundation Pompe osmotique à libération modifiée pour administration intravaginale de médicament réagissant au ph
WO2014124504A1 (fr) 2013-02-13 2014-08-21 Katholieke Universiteit Leuven Ku Leuven Research & Development Compositions et méthodes de traitement de biofilms
US9919055B2 (en) 2013-03-15 2018-03-20 Arizona Board Of Regents On Behalf Of Arizona State University Sugar-linker-drug conjugates
JP6254257B2 (ja) 2013-05-01 2017-12-27 ネオクリ ピーティーワイ リミテッド 細菌感染を処置するための方法
US20160213742A1 (en) 2013-09-04 2016-07-28 Cidara Therapeutics, Inc. Compositions and methods for the treatment of fungal infections
EP3265143A4 (fr) * 2015-03-02 2018-08-29 Commonwealth Scientific & Industrial Research Organisation ( C.S.I.R.O. ) Procédés pour influer négativement des biofilms
WO2017049105A1 (fr) 2015-09-16 2017-03-23 Cidara Therapeutics, Inc. Formulations pour le traitement d'infections fongiques
US20180256673A1 (en) 2015-09-16 2018-09-13 Cidara Therapeutics, Inc. Methods for treating fungal infections
EP3399995A4 (fr) 2016-01-08 2019-08-21 Cidara Therapeutics, Inc. Procédés de prévention et de traitement d'infections à pneumocystis
CA3017485A1 (fr) 2016-03-16 2017-09-21 Cidara Therapeutics, Inc. Schemas posologiques pour le traitement d'infections fongiques
EP3534927A4 (fr) 2016-11-01 2020-07-29 Cidara Therapeutics, Inc. Méthodes à dose unique pour la prévention et le traitement d'infections fongiques
US20210002346A1 (en) 2016-11-29 2021-01-07 Cidara Therapeutics, Inc Methods for preventing fungal infections
EP3577129A1 (fr) 2017-01-31 2019-12-11 Cidara Therapeutics, Inc. Procédés de traitement d'infections fongiques
WO2018187574A1 (fr) 2017-04-05 2018-10-11 Cidara Therapeutics, Inc. Compositions et procédés de traitement d'infections fongiques
WO2018191692A1 (fr) 2017-04-14 2018-10-18 Cidara Therapeutics, Inc. Procédés de traitement d'infections fongiques
JP2020529973A (ja) 2017-07-12 2020-10-15 シダラ セラピューティクス インコーポレーテッド 真菌感染症の処置のための組成物及び方法
US20200164023A1 (en) 2017-08-03 2020-05-28 Cidara Therapeutics, Inc. Methods for preventing and treating intra-abdominal candidiasis
AU2019287621A1 (en) 2018-06-15 2021-01-28 Cidara Therapeutics, Inc. Synthesis of echinocandin antifungal agent

Also Published As

Publication number Publication date
EP3651801A1 (fr) 2020-05-20
US20220323539A1 (en) 2022-10-13
WO2019014333A9 (fr) 2019-03-28
US11819533B2 (en) 2023-11-21
US20200268833A1 (en) 2020-08-27
EP3651801A4 (fr) 2021-04-07
JP2023134427A (ja) 2023-09-27
CA3069423A1 (fr) 2019-01-17
JP2020529973A (ja) 2020-10-15
WO2019014333A1 (fr) 2019-01-17
CN111050798A (zh) 2020-04-21
US11197909B2 (en) 2021-12-14

Similar Documents

Publication Publication Date Title
MA45539A (fr) Dihydropyranopyrimidines pour le traitement d'infections virales
MA50877A (fr) Matériaux et méthodes pour le traitement de la rétinite pigmentaire autosomique dominante
MA43135A (fr) Compositions et méthodes pour le du traitement du cancer
MA45192A (fr) Traitement d'association
MA49576A (fr) Compositions et méthodes pour le traitement d'infections fongiques
MA52232A (fr) Inhibiteurs hétérobicycliques de mat2a et leurs méthodes d'utilisation pour le traitement du cancer
MA44083A (fr) Composés de biarylmonobactame pour le traitement d'infections bactériennes
MA49144A (fr) Polythérapies pour le traitement du cancer
MA46954A (fr) Méthodes de traitement d'états inflammatoires
MA47310A (fr) Combinaisons de cabozantinib et d'atzolizumab pour traiter le cancer
MA40867A (fr) Méthodes pour le traitement d'infections virales à filoviridae
MA55629A (fr) Compositions d'anticorps pour le traitement de tumeurs
MA47719A (fr) Esketamine pour le traitement de la dépression
MA43811A (fr) Composés d'arylmonobactame bicycliques et leurs méthodes d'utilisation pour le traitement des infections bactériennes
MA48637A (fr) Polythérapies pour le traitement du cancer
MA50409A (fr) Polythérapies pour le traitement du cancer
MA52861A (fr) Méthodes et compositions pour le traitement de l'apnée du sommeil
MA51056A (fr) Compositions et méthodes pour le traitement d'affections métaboliques
MA43230A (fr) Méthodes et compositions pour le traitement d'une épidermolyse bulleuse
MA53873A (fr) Compositions et procédés pour le traitement de la presbytie
MA45552A (fr) Compositions destinées au traitement de l'amylose
MA43825A (fr) Schémas posologiques pour le traitement d'infections fongiques
MA45226A (fr) Compositions et méthodes de traitement ou de prévention d'affections liées à l'oxalate
MA47437A (fr) Procédés de traitement d'infections fongiques
MA41629A (fr) Compositions et méthodes d'utilisation de l'hormone anti-müllérienne pour le traitement de l'infertilité